ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » SLE – Diagnosis, Manifestations, & Outcomes Poster II

Date: Sunday, November 17, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM
Abstract Number: 1484
A Retrospective Evaluation of Glucagon-like Peptide-1 Receptor Agonists in SLE Patients
10:30AM-12:30PM
Abstract Number: 1513
Assessing Subjective Cognitive Impairment in a Cohort of Canadian Systemic Lupus Erythematosus Patients: Construct Validity of PDQ-20
10:30AM-12:30PM
Abstract Number: 1512
Association Between the Systemic Immune Inflammatory Index (Sll) and All-cause Mortality in Critically Ill Patients with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1530
Belimumab-Treated Patients with Systemic Lupus Erythematosus Without Prior Immunosuppressant Use Have More Favorable Clinical Outcomes Than Those with Prior Use of an Immunosuppressant
10:30AM-12:30PM
Abstract Number: 1486
Cardiovascular Risk in Systemic Lupus Erythematosus: Carotid Ultrasonography Is Useful for the Re-stratification of Cardiovascular Risk Determined by Score2
10:30AM-12:30PM
Abstract Number: 1508
Clinical Characteristics and Prognosis of Late-onset Systemic Lupus Erythematosus in 305 Japanese Patients
10:30AM-12:30PM
Abstract Number: 1488
Clinical Utility and Performance of Anti-C1q Antibodies for Systemic Lupus Erythematosus: Comparative Analysis of Three Different Assays
10:30AM-12:30PM
Abstract Number: 1506
Cognitive Impairment Prevalence and Most Affected Domains in Patients with SLE by the ACR Comprehensive Neuropsychological Battery
10:30AM-12:30PM
Abstract Number: 1527
Comparative Harms in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab or Belimumab: A Multicenter Cohort Study Using the TriNetX Research Network
10:30AM-12:30PM
Abstract Number: 1521
Contemporary Lupus Nephritis Treatment and Outcomes Among Patients with Systemic Lupus Erythematosus in the United States
10:30AM-12:30PM
Abstract Number: 1517
Diagnostic Performance of Anti-dsDNA Antibodies in Pleural, Ascitic and Pericardial Fluid for Lupus Serositis: Experience of a Tertiary Center in Mexico
10:30AM-12:30PM
Abstract Number: 1516
Diagnostic Performance of Anti-ribosomal P Antibodies in Cerebrospinal Fluid of Neuropsychiatric Systemic Lupus Erythematosus with Diffuse Central Nervous System Manifestations. Experience in a Tertiary Center in Mexico
10:30AM-12:30PM
Abstract Number: 1496
Dysregulated Serum Cytokines in Association with Clinical Manifestations in Patients with Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1525
Early versus Late Lupus Nephritis: A Meta-analysis of Observational Studies
10:30AM-12:30PM
Abstract Number: 1498
Gender Disparities in Clinical Manifestations and Outcomes of Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
10:30AM-12:30PM
Abstract Number: 1485
Genetic Contributions to Systemic Lupus Erythematosus: Concordance Rates in California Twins
10:30AM-12:30PM
Abstract Number: 1493
How Do Lupus Nephritis Patients Who Achieve Renal Remission Fare? A 3-year Comparison in Terms of GFR Decline
10:30AM-12:30PM
Abstract Number: 1514
Immunosenescent and Exhausted T Cells in Patients with Systemic Lupus Erythematosus and Cognitive Impairment
10:30AM-12:30PM
Abstract Number: 1510
Impact of Active Lupus Nephritis on the Quality of Life of Patients from a Latin American Lupus Cohort
10:30AM-12:30PM
Abstract Number: 1522
Impact of Thrombocytopenia on In-hospital Mortality and Healthcare Resource Utilization in Patients with Systemic Lupus Erythematosus: An Analysis of the National Inpatient Sample Database 2020
10:30AM-12:30PM
Abstract Number: 1515
Incidence and Predictors of Neuropsychiatric Lupus—a Contemporary Cohort Study Across the United States
10:30AM-12:30PM
Abstract Number: 1505
Incidence of Cardiovascular and Venous Thromboembolic Events in Four Autoantibody-defined Systemic Lupus Erythematosus Clusters
10:30AM-12:30PM
Abstract Number: 1519
Incidence, Risk Factors, and Outcomes of Severe Lymphopenia in Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1511
Lupus Nephritis and Response to Treatment in Latin America
10:30AM-12:30PM
Abstract Number: 1489
Lupus Nephritis Clinical and Serological Responses at 12 Months: Implications for Repeat Biopsy, Intensified Immunosuppression or Additional Anti-proteinuric Therapy
10:30AM-12:30PM
Abstract Number: 1490
Multi-centered Clinical Validation of T Cell-bound C4d (TC4d) and T Cell Autoantibodies (TIgG and TIgM): Sensitive and Specific Biomarkers of SLE with Enhanced Accuracy Compared to Conventional SLE Tests
10:30AM-12:30PM
Abstract Number: 1504
Novel Analytes Associated with Cognitive Impairment in Patients with Systemic Lupus Erythematosus: Serum S100A8/A9, MMP-9 and IL-6
10:30AM-12:30PM
Abstract Number: 1499
Outcome of Newly Onset SLE with Neuropsychiatric Symptoms and Its Clinical Features in Daily Clinical Practice: A Single Center Study
10:30AM-12:30PM
Abstract Number: 1518
Predictive Value of Chronic Histologic Changes in Lupus Nephritis
10:30AM-12:30PM
Abstract Number: 1487
Pregnancy Outcome and Risk Factors Analysis in Patients with Systemic Lupus Erythematosus Complicated with Thrombocytopenia
10:30AM-12:30PM
Abstract Number: 1528
Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: National Inpatient Sample Analysis
10:30AM-12:30PM
Abstract Number: 1483
Real World Data on Infections from the Indian SLE Inception Cohort for Research (INSPIRE): Spectrum and Risk Factors
10:30AM-12:30PM
Abstract Number: 1495
Real-World Reduction in Disease Flares and Oral Corticosteroid Use with Anifrolumab Therapy in Systemic Lupus Erythematosus: A Claims-Based Study
10:30AM-12:30PM
Abstract Number: 1501
Retrospective Cohort Study Identifying Pulmonary Complications in a Cohort of Patients with Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1491
Self-Reported Cognitive Function Among Older Adults with Systemic Lupus Erythematosus (SLE) Compared to Older Adults with Other Rheumatic and Musculoskeletal Conditions
10:30AM-12:30PM
Abstract Number: 1503
Social Connections Among Middle-Aged and Older Adults with Systemic Lupus Erythematosus: A Single Center Cross-Sectional Study
10:30AM-12:30PM
Abstract Number: 1529
Systemic Lupus Erythematous and Neuromyelitis Optica Overlap and Risk of Infection in Hospitalized Patients
10:30AM-12:30PM
Abstract Number: 1520
The Influence of Trauma on Features of Type 2 SLE
10:30AM-12:30PM
Abstract Number: 1502
The Systemic Lupus International Collaborating Clinics (SLICC) Frailty Index (SLICC-FI) Predicts Hospitalizations. Data from the Almenara Lupus Cohort
10:30AM-12:30PM
Abstract Number: 1524
Thrombocytopenia and Systemic Lupus Erythematosus: A Meta-analysis of Observational Studies
10:30AM-12:30PM
Abstract Number: 1492
Timing of SLEDAI-2K Item Improvements During the First Year of Intravenous Anifrolumab Treatment of Moderate to Severe SLE
10:30AM-12:30PM
Abstract Number: 1507
To Develop a Method for Estimating Interferon Signatures in SLE from Routine Clinical Laboratory Tests
10:30AM-12:30PM
Abstract Number: 1494
Trajectories of Disease Evolution upon Treatment Initiation in Systemic Lupus Erythematosus: Pooled Results from Three Randomized Clinical Trials of Belimumab
10:30AM-12:30PM
Abstract Number: 1523
Trend Analysis of Lupus Nephritis Flares, Mortality, and Disparities: 2016-2020
10:30AM-12:30PM
Abstract Number: 1497
Type I Interferon Status and Clinical Manifestations in a Large Cohort of Patients with Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1526
Utilizing Electronic Health Records to Identify Clinical Features of ANA-Positive Patients Imparting High Risk for Progression to Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1509
Validation of a Score for the Prediction of Serious Infection in Patients with Systemic Lupus Erythematosus: Data from a Latin American Lupus Cohort
10:30AM-12:30PM
Abstract Number: 1500
Work-Related Disability and Function in Systemic Lupus Erythematosus (SLE): Outcomes of an Exploratory Study from Different Canadian Centres

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology